Kinase Inhibitor News and Research

RSS

A protein kinase inhibitor is a type of enzyme inhibitor that specifically blocks the action of one or more protein kinases.

Researchers find new target for disease of the heart's smallest blood vessels

When we race walk, for example, part of our healthy heart muscle may want a little more blood and oxygen, so our tiniest blood vessels send a message upstream to the larger vessels to send more.

12 Aug 2019

New drug combinations and dosing schedules improve outlook in advanced colon cancer

Advanced colon cancer often spreads widely and may not respond to standard chemotherapy. In such a case, a novel combination of drugs and flexible dosing may help achieve a better outlook, as demonstrated by several new studies.

8 Jul 2019

Study suggests usefulness of more flexible dose of regorafenib to relieve side-effects in mCRC patients

Medical oncologists administer anticancer drug regorafenib to try to improve overall survival in patients with metastatic colorectal cancer who have ceased to respond to standard therapy (known as refractory mCRC).

7 Jul 2019

Study shows how SIRT1 plays key role in maintaining the regenerative potential of leukemic stem cells

Patients with chronic myeloid leukemia can be treated with tyrosine kinase inhibitors. While these effective drugs lead to deep remission and prolonged survival, primitive leukemia stem cells resist elimination during the remission and persist as a major barrier to cure.

11 Jun 2019

Still-to-be-approved drug proves to be new option for treating active rheumatoid arthritis

In a large-scale, international study led by renowned rheumatologist Josef Smolen from the Department of Medicine III, a still-to-be-approved drug containing the selective janus kinase inhibitor upadacitinib has proved itself to be a new option for treating active rheumatoid arthritis.

7 Jun 2019

Researchers discover unique approach to treat some chronic inflammatory diseases

Inflammation is a balanced physiological response -- the body needs it to eliminate invasive organisms and foreign irritants, but excessive inflammation can harm healthy cells, contributing to aging and chronic diseases.

12 Apr 2019

Scientists use a promiscuous inhibitor to uncover cancer drug targets

Scientists at Harvard Medical School and the Dana-Farber Cancer Institute have developed a method that exploits the multitargeted nature of a chemical inhibitor to pinpoint vulnerabilities within cancer cells.

5 Apr 2019

FDA extends indication of metastatic breast cancer treatment to include male patients

The U.S. Food and Drug Administration today is extending the indication of Ibrance (palbociclib) capsules in combination with specific endocrine therapies for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in male patients.

5 Apr 2019

Understanding maintenance of quiescent stem cells in chronic myelogenous leukemia

Most patients with chronic myelogenous leukemia can be treated with tyrosine kinase inhibitors. These drugs are highly effective and lead to deep remission and prolonged survival.

22 Mar 2019

New research finds how cancer cells acquire resistance to molecular-targeted drugs

Although molecular-targeted drugs have been known to show high efficacy to lung cancer patients, they also have limitations due to acquiring resistance to the drug used.

25 Feb 2019

Researchers discover origin of resistance to lung cancer

For treating cancer, drugs based on molecules known as tyrosine kinase inhibitors are sometimes used. One such tyrosine kinase inhibitor, called osimertinib, has been used to treat EGFR-mutated lung cancer with a certain degree of efficacy.

25 Feb 2019

Bio-Rad launches new digital PCR system and kit for monitoring treatment response in CML patients

Bio-Rad Laboratories, Inc., a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad's Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry's first digital PCR products to receive U.S. Food and Drug Administration clearance.

15 Feb 2019

Researchers identify promising therapeutic option to treat multiple sclerosis

Researchers at the Medical Center of Johannes Gutenberg University Mainz (JGU) identified an innovative and promising therapeutic option to treat multiple sclerosis.

10 Jan 2019

New drug combination could kill melanoma cells more effectively, study shows

A class of cancer drugs called protein kinase inhibitors is one of the most effective treatments for melanoma. However, in many cases, tumors eventually become resistant to the drugs and cause a relapse in the patient.

3 Dec 2018

Triple combination cancer immunotherapy improves survival in mouse model of melanoma

Adoptive cell transfer is a promising cancer immunotherapy that involves isolating T cells from cancer patients that are capable of targeting their tumor, selecting the more active T cells and expanding those in the lab, and then transfusing them back into patients.

30 Nov 2018

FDA approves LORBRENA for treatment of patients with ALK-positive metastatic NSCLC

Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved LORBRENA, a third-generation anaplastic lymphoma kinase tyrosine kinase inhibitor for patients with ALK-positive metastatic non-small cell lung cancer whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

5 Nov 2018

Study offers new hope to patients with rare brain cancer

sGBM is a rare type of brain cancer in adults. The incidence varies from 2 to 5 per million people per year. For example, if Hong Kong's base population of 7.5 million people is taken as a reference, over 15 people will be diagnosed with sGBM tumors annually.

2 Nov 2018

Study shows potential of avelumab plus axitinib as new treatment option for patients with advanced RCC

A combination of the immune checkpoint blocker, avelumab, plus the tyrosine kinase inhibitor, axitinib, significantly improves progression-free survival in previously untreated patients with advanced renal cell carcinoma in a phase 3 study, according to results presented at ESMO 2018 Congress.

22 Oct 2018

Study: Erlotinib improves progression-free survival in EGFR mutated NSCLC

Neoadjuvant erlotinib benefits selected epidermal growth factor receptor (EGFR)-mutated patients who undergo complete resection of stage IIIA-N2 stage non-small cell lung cancer(NSCLC), shows a randomized study comparing erlotinib with gemcitabine plus cisplatin as neoadjuvant treatment, presented at the ESMO 2018 Congress in Munich.